Interleukin-62/lymphocyte as a proposed predictive index for COVID-19 patients treated with monoclonal antibodies
Description
In a convenience sample of 93 patients treated with monoclonal antibodies (moAbs) against SARS-CoV-2, the interleukin-6²/lymphocyte count ratio (IL-6²/LC) was able to predict clinical worsening both in early stages of COVID-19 and in oxygen-requiring
